Kornimate/medical-research-clean huggingface dataset:
effectiveness of transverse friction massage in latent myofascial trigger points in anterior deltoid muscle

Conditions: Myofascial Trigger Points; Myofascial Pain

Summary: the purpose of this study is to determine whether transverse friction massage (tfm) in latent myofascial trigger points (mtrp) is more effective making this technique in two different ways.

the investigators divide in two groups. the investigators apply the tfm in similar way in both, but the investigators cause local twitch response (isolated contraction of muscle fibers containing the latent trigger points)just in one group. so the investigators want to know whether the effectiveness of this technique is due to those local twitch responses, comparing both groups. the investigators asses strength, range of motion, and overall, pressure pain thresholds to evaluate the pain sensitivity progress.

Eligibility criteria:
inclusion criteria: * having latent myofascial trigger points in anterior deltoid * visual local twitch response exclusion criteria: * having active myofascial trigger points in anterior deltoid * having suffered injuries or surgery in upper limb. * pain in the first evaluation session. * not obtaining local twitch response

Keywords: latent myofascial trigger point. transverse friction massage local twitch response effectiveness
interest of positive expiratory pressure (pep) delivery by ezpap® after cardiac surgery in the management of postoperative atelectasis

Conditions: Pulmonary Atelectasis

Summary: pulmonary atelectasis is a frequent respiratory postoperative complication in cardiac surgery. classically, the treatment of these patients is based on manual chest physiotherapy. our objective is to evaluate the interest of association of positive end expiratory delivery sessions with the ezpap® device. we perform a prospective monocentric, open label trial. patients with atelectasis after scheduled cardiac surgery with cardiopulmonary bypass are included. they benefit from manual chest therapy and are randomised to receive or not positive end expiratory pressure sessions twice a day. the primary endpoint is the effect of this treatment on atelectasis radiological score after 2 days of treatment. the secondary endpoints are: oxygen saturation(spo2)/inspired oxygen(fio2) ratio, qualitative evaluation of ventilatory function, respiratory \& cardiac rate, pain, inspiratory pressure (sniff test), patient satisfaction, duration of intensive care unit (icu) and hospital stay.


Eligibility criteria:
inclusion criteria: * patients admitted in icu after cardiac surgery by sternotomy with cardiopulmonary bypass presenting a pulmonary atelectasis after extubation, diagnosed by chest x-ray in postoperative period (day1 to day 2). * patients over 18 years of age * informed patient exclusion criteria: * cardiac arrhythmia * hemodynamic instability (mean blood pressure \ 95 mmhg) * respiratory rate \> 35/min * undrained pneumothorax * predictable trachea intubation or emergent surgery * patient oral refusal

Keywords: atelectasis, respiratory physiotherapy, end expiratory pressure, ezpap®, cardiac surgery
spanish registry of patients with sleep apnea and daytime sleepiness

Conditions: Sleep Apnea

Summary: multicenter, observational and prospective study, in which patients referred to the sleep unit with suspected apnea will be recruited obstructive sleep. 1000 patients referred to the sleep unit will be recruited with suspected obstructive sleep apnea. the recruited patients will undergo a sleep study for the diagnosis of osa, ambulatory monitoring of blood pressure (abp) of 24 hours, clinical variables will be obtained, questionnaires of quality of life, epworth test for the evaluation of daytime sleepiness, variables biochemistry and obtaining biological samples. osa patients will be managed following the usual practice. in those patients for whom the treatment with cpap an evaluation of adherence to treatment will be carried out. osa patients will be evaluated at baseline, 6, 12, and 24 months.


Eligibility criteria:
inclusion criteria: * patients who come to the sleep consultation for sleep study results for suspected osa. * patients older than 18 years. * signature of the informed consent. exclusion criteria: * psycho-physical inability to complete questionnaires. * presence of any previously diagnosed sleep disorder: narcolepsy, insomnia, sleep deprivation (less than 6h/day), regular use of medications hypnotics or sedatives (may be included if you only use a short-acting benzodiazepine or melatonin) and restless legs syndrome. * patients with \> 50% central apnea or presence of cheyne-stokes respiration (csrsp). * a medical history that may interfere with the objectives of the study or that in the judgment of the investigator compromises the conclusions. * any medical, social or geographical factor that may endanger the patient compliance. (eg, alcohol consumption (more than 80 g/day in men and more than 60 gr / day in women), absence of stable habitual residence, disorientation or non-compliance history). * any process, cardiovascular or not, that limits life expectancy to less than one year.

Keywords: cpap, residual sleepiness, osa
treatment of dysglycemia using sitagliptin in adolescents with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: this pilot study will be conducted in adolescents with cystic fibrosis (cf) without diabetes but with abnormal glucose tolerance, and will assess the effects of sitagliptin on glucose regulation. an oral glucose tolerance test (ogtt) and a mixed meal tolerance test (mmtt), will be performed at baseline and again \~4 weeks after treatment with study drug. we will also look at blood sugars throughout the day using a continuous glucose monitor (cgm) before each time the mmtt/ogtt are performed. several hormones that may affect the way the body regulates blood sugars will be measured in blood when the ogtt and mmtt are done. we will assess the effect this medicine has on blood sugars (using cgm) and the effect the medicine has on the hormones measured during the ogtt and mmtt.


Eligibility criteria:
inclusion criteria: * patients with cf between 13 and \<21 yrs old * known impaired or indeterminate glucose tolerance (based on a prior ogtt) * no history of cfrd exclusion criteria: * insulin use in the last two months * acute pulmonary exacerbation / oral corticosteroid use in the last 6 weeks * history of pancreatitis in the last 12 months * skin rashes or conditions that may affect cgm placement and wear * pregnancy or intent on becoming pregnant * patients on growth hormone therapy * renal insufficiency with creatinine clearance \<50 ml/min (based on schwartz formula)

Keywords: cystic fibrosis cf cfrd sitagliptin incretins glp1 gip beta cell function adolescents
a comparison of methylphenidate and cognitive behavioural therapy for the treatment of binge eating disorder

Conditions: Binge-Eating Disorder

Summary: the purpose of this study is to determine whether methylphenidate is effective in the treatment of binge eating disorder, in a randomized controlled trial extended release methylphenidate versus cognitive behavioral therapy for binge eating disorder in overweight or obese adult females.

fifty-six adult female outpatients with binge eating disorder will receive 12 weeks of methylphenidate (dosage 18-72 mg) or 12 sessions of manualized cognitive behavioral therapy. participants will complete interviewer-rated and self-report measures of eating, mood, attention, and personality features before treatment, after 6 weeks of treatment, immediately after treatment is completed, and 3 months after treatment is completed.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of binge-eating disorder according to the diagnostic and statistical manual of mental disorders, fifth edition * body mass index ≥ 25 * must be fluent in english * must be capable to give informed consent exclusion criteria: * current pregnancy or lactation * psychotherapy or behavioural treatment for eating or weight initiated during the past month * psychotropic or investigational medications initiated / changed during the past three months * concomitant use of another psychostimulant * current mental disorders that are acute/unstable, that require alternate treatment, and/or that preclude ability to complete research protocol including mania, psychosis, substance use (alcohol or drugs), dementia, organic brain disorders, mental retardation * current severe suicidality or homicidality * current uncontrolled medical conditions that affect weight or bed symptoms or that are contraindicated for methylphenidate including metabolic, neurological, hepatic, renal, cardiovascular, hematological, ophthalmic, or endocrine diseases * other serious medical illness or event such as acute myocardial infarction or stroke during the past six months * history of seizures or tics in the past year * diagnosis or family history of tourette's * clinically relevant laboratory results, including: tachycardia as indicated by heart rate \> 110; hypertension as indicated by blood pressure parameters \> 140 (systolic) and 90 (diastolic); arrhythmias or conduction abnormalities as indicated by ecg parameters qtc\> 460msec, qrs\>120 msec, and pr\>200 msec; abnormal laboratory results (e.g., hypokalemia) as indicated by values \> 20% above the upper range of the laboratory standard of a basic metabolic screen * current medications that affect weight * current medications that are contraindicated for methylphenidate
mri biomarkers in als

Conditions: Amyotrophic Lateral Sclerosis; ALS; Motor Neuron Diseases

Summary: amyotrophic lateral sclerosis (als) is a disabling and rapidly progressive neurodegenerative disorder. there is no treatment that significantly slows progression. increasing age is an important risk factor for developing als; thus, the societal impact of this devastating disease will become more profound as the population ages. a significant hurdle to finding effective treatment has been an inability to accurately measure brain degeneration in humans. advanced magnetic resonance imaging (mri) techniques hold promise in this respect, and may assist in aiding diagnosis and the efficient testing of new drugs. different mri features of brain degeneration will be measured in a large sample of patients with als. the study will operate within the canadian als neuroimaging consortium (calsnic). calsnic is a clinical research platform comprised of als clinics with standardized clinical and neuroimaging protocols.

this study will use advanced magnetic resonance imaging (mri) techniques to measure brain changes in als and related neurological conditions. results from cognitive and neurological tests will be compared to the mri. it is believed that these techniques will reveal changes in the brain that will help us understand normal brain function and the symptoms of neurological diseases as seen in als, as well to provide an objective measurement of degeneration (which is called a biomarker). this could improve not only the process by which new drugs for the treatment of neurological diseases are evaluated, but also how health care professionals address the needs of patients with these diseases. furthermore, a biomarker may give insight into the biological factors related to the diverse and variable clinical features amongst different patients. subjects will be recruited from als clinics that are a part of the canadian als neuroimaging consortium (calsnic). patients will have a diagnosis of als, pls, pma, or ftd. healthy controls will be age and gender matched to patients. subjects will visit their respective sites to undergo a clinical evaluation and an mri. follow up visits will occur at approximately 3-6 month intervals. most subjects will have 2 follow up visits; more visits may occur for subjects who are physically able to continue in the protocol.

Eligibility criteria:
inclusion criteria: * patients will be adults with a diagnosis of motor neuron disease (mnd), including those with als, pls, and pma, and as well frontotemporal dementia (ftd) without motor neuron signs. * healthy controls over the age of 40 will also be recruited and will be age- and gender-matched to patients. exclusion criteria: * subjects with other psychiatric/cns illnesses such as major depressive disorder, schizophrenia, and bipolar disorder, and those with significant head injury. * subjects ineligible for mri investigation due to a pacemaker or other metallic foreign body, or significant claustrophobia that could affect the ability to have an mri scan. these exclusion criteria will also apply to controls.

Keywords: magnetic resonance imaging mri biomarker
evaluation of meibomian gland dysfunction before and after cataract surgery

Conditions: Cataract Patients

Summary: this study will compare cataract patients before and after phacoemulsification. evaluations will be performed before and 1 and 3 months following cataract surgery, including parameters of dry eye syndrome and mgd. dry eye syndrome parameters included tbut, schirmer's test type i, oxford staining score, and the ocular surface disease index (osdi) questionnaire. mgd parameters consisted of lipid layer thickness (llt), lid margin abnormality, meibum quality, meibum expressibility, mg orifice obstruction, mgd stage, and mg dropout.


Eligibility criteria:
inclusion criteria: * patients with cataract surgery planning with phacoemulsification and intraocular lens implantation with or without mild dry eye syndrome exclusion criteria: * the previous use of eye drops, except artificial tears within 3 months before cataract surgery * a history of previous ocular surgery or trauma * the presence of ocular comorbidities such as glaucoma, uveitis, cystoid macular edema, and any surgical complications including rupture of the posterior capsule during cataract surgery.
an extension study to determine the persistence of tick-borne encephalitis (tbe)-specific antibody responses among children and adolescents previously immunized against tbe

Conditions: Tick Borne Encephalitis (TBE)

Summary: this study will evaluate the durability of antibody responses in children and adolescents after primary immunization with tbe vaccine


Eligibility criteria:
inclusion criteria: * healthy study subjects from the parent study who completed the primary vaccination series, with parental or legal guardian informed consent exclusion criteria: * subjects who did not receive complete schedule of primary vaccination in the parent study * subjects enrolled in other investigational studies at the same time and within the last three months * subjects with any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives

Keywords: tbe tick borne encephalitis
enzalutamide and hormone therapy before, during, and after radiation for high risk localized prostate cancer

Conditions: Prostate Cancer

Summary: the study is being done to find out whether combining two fda approved drugs along with radiation therapy for the treatment of high risk localized prostate cancer is safe and well tolerated.

* this pilot study will assess the safety and tolerability of combining enzalutamide with an gonadotropin-releasing hormone agonist (gnrh) and external beam radiation * correlative imaging and tissue biopsy analysis will be performed to assess the radiographic response to enzalutamide plus gonadotropin-releasing hormone agonist (gnrh) therapy as well as intratumoral androgen signaling

Eligibility criteria:
inclusion criteria: * histologically proven adenocarcinoma of the prostate within 6 months of screening * eastern cooperative oncology group(ecog) score 0-2 * adequate organ and and blood marrow function * must be a candidate for long-term androgen deprivation in combination with external beam radiation for the treatment of high risk prostate cancer * patient must permit a targeted prostate biopsy at the time of study initiation or at the beginning of radiation treatment * men who are sexually active with female partners of child-bearing potential mush agree to use adequate contraception exclusion criteria: * prior treatment with agents known to have endocrine effects on prostate cancer * treatment with corticosteroids within 4 weeks of enrollment * treatment with androgens within 6 months of enrollment * may not be receiving any other investigational agents * prostate specific antigen greater than 160ng/dl * history of malignancy( other than non-melanoma skin cancer) within 5 years * uncontrolled intercurrent illness * cardiovascular event within 6 months of enrollment * seizure or seizure disorder history * contraindications to mri- pacemakers, clips, etc

Keywords: prostate cancer, enzalutamide, radiation, hormone therapy
cardiac function and inspiratory muscles performance

Conditions: Heart Failure

Summary: the purpose of this study is to determine whether ejection fraction and peak oxygen uptake have correlation on inspiratory muscle strength, chest wall volumes and quality of life in individuals with heart failure.


Eligibility criteria:
inclusion criteria: * will be included individuals diagnosed with heart failure, both sexes, aged 18-65 years; * hemodynamically stable (systolic blood pressure ≤ 140 mmhg; diastolic blood pressure ≤ 90 mmhg; heart rate = 90 bpm); * self-reported sedentary. exclusion criteria: * will be excluded individuals with unstable angina were excluded; * acute myocardial infarction or previous surgery up to three months before the survey; * musculoskeletal changes, respiratory or chronic metabolic diseases; * treatment with steroids, hormones or chemotherapy; * gestation; * smokers and former smokers assets or liabilities; * inability to comply with verbal commands appraiser or unsuitability to the evaluation devices.

Keywords: left ventricular ejection fraction peak oxygen uptake respiratory muscles quality of life
a registry based collaborative to measure efficiency, effectiveness, and safety of farapulse pfa technology for af

Conditions: Atrial Fibrillation

Summary: the disrupt-af registry is an observational, prospective, multi-center, non-randomized, real-world registry designed to obtain clinical experience with the farapulse pulsed field ablation system for the treatment of atrial fibrillation (af).

the disrupt-af registry is an observational, prospective, multi-center, non-randomized, real-world registry designed to obtain clinical experience with the farapulse pulsed field ablation system for the treatment of atrial fibrillation (af). all types of af including paroxysmal, persistent and long standing persistent may be included. the registry has three cohorts: 1) acute arm, 2) symptomatic monitoring only arm, and 3) full monitoring arm. in the acute arm, patient assessments will occur at pre- procedure and procedure visits. in both the symptomatic monitoring only arm and the full monitoring arm, patient assessments will occur at pre- procedure, procedure, 3 months, and 1 year post ablation. additionally, the full monitoring arm will assess for asymptomatic recurrence at 6- and 12-months post-ablation. sites will be assigned to an arm in which they will enroll under based on their practices current standard of care. sites can only participate in one arm. the primary purpose of the registry is to assess clinical outcomes, including procedural efficiency, safety, and long-term effectiveness of pulsed field ablation (pfa) in the treatment of patients with af. also, to assess the effect of pfa technology implementation on practice patterns, operational workflow and operator experience. the registry will utilize real world clinical data obtained from the use of commercially available technologies under the authority of a health care practitioner within a legitimate practitioner-patient relationship.

Eligibility criteria:
inclusion criteria: * patients who, in the opinion of the investigator, are candidates for ablation for af * plans to undergo an ablation procedure using the farapulse pulsed field ablation system manufactured by boston scientific * de novo ablation unless it is a repeat procedure for a subject whose index procedure is also included in the registry * 18 years of age or older * able and willing to participate in baseline and follow up evaluations for the full length of the registry exclusion criteria: * enrolled in an investigational drug or device trial, or any trial that dictates the treatment plan without prior approval from sponsor * prior left atrial ablation (catheter or surgical) * currently receiving inotropic or mechanical support * in the opinion of the investigator, any known contraindication to an ablation procedure or to any device or drug required for use during an ablation procedure as assessed by the investigator

Keywords: paroxysmal atrial fibrillation persistent atrial fibrillation long-standing persistent atrial fibrillation pulse field ablation
evaluating the effects of tasimelteon vs. placebo in delayed sleep-wake phase disorder (dswpd)

Conditions: Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders

Summary: this is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with dswpd.


Eligibility criteria:
inclusion criteria: * ability and acceptance to provide written informed consent. * a confirmed clinical diagnosis of delayed sleep-wake phase disorder (dswpd). * men or women between 18 - 75 years, inclusive. * body mass index (bmi) of ≥ 18 and ≤ 35 kg/m\^2. exclusion criteria: * exacerbation of an existing psychiatric condition that requires change in treatment or intervention in the past 3 months. * major surgery, trauma, illness, general anesthesia, or immobility for 3 or more days within the last 30 days. * pregnancy, recent pregnancy (within 6 weeks), or women who are breastfeeding. * a positive test for substances of abuse. * current tobacco user.
cotton sock in pediatric patients with leg-foot splint

Conditions: Flat Foot

Summary: the post-operative treatment of pediatric patients operated for the correction of flat foot, sees today the use of preformed leg-foot splint (walker) as an alternative to the application of plaster casts. the change of the immobilization system has led to the appearance of problems of tolerability in particular in the skin. the problems persist also after placing a polyurethane foam dress at the heel in the immediate postoperative period. the aim of this study is to evaluate the effectiveness of a cotton sock applied inside the leg-foot splint in children operated vs the elastic compression wraps in reducing the incidence of cutaneous lesions.


Eligibility criteria:
inclusion criteria: * children aged \> 3 years * treated for flat foot * children with intact skin at the heel exclusion criteria: * caregivers who cannot speak italian * those who refuse to give their consent to take part in the study * patients with lower limb casts